The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy

Hepatology. 2015 Sep;62(3):975. doi: 10.1002/hep.27600. Epub 2015 Feb 17.

Authors

Marcella Visentini¹, Stefania Colantuono¹, Guido Granata¹, Adriano de Santis², Massimo Fiorilli¹, Milvia Casato¹

Affiliations

¹ Referral Center for Mixed Cryoglobulinemia, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.
² Division of Gastroenterology and Hepatology, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.

PMID: 25380535
DOI: 10.1002/hep.27600

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Cohort Studies
Cost-Benefit Analysis
Cryoglobulinemia / economics
Cryoglobulinemia / immunology
Cryoglobulinemia / therapy*
Female
Hepacivirus / immunology*
Hepatitis C, Chronic / immunology
Hepatitis C, Chronic / mortality
Hepatitis C, Chronic / therapy*
Hospitalization / economics
Humans
Immunotherapy*
Interferons / therapeutic use
Male
Middle Aged
Retrospective Studies
Risk Assessment
Sensitivity and Specificity
Severity of Illness Index
Survival Rate
Vasculitis / economics
Vasculitis / immunology
Vasculitis / therapy*

Substances

Interferons